Login to Your Account

IO's promise: A future of combo therapies, complementary Dx

By Karen Pihl-Carey
Staff Writer

Tuesday, June 7, 2016

CHICAGO – Immunotherapy is increasingly becoming a pillar of cancer treatment, as checkpoint inhibitors continue to demonstrate tumor regression and survival benefits, and a growing body of biomarker research informs treatment decisions.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription